Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03923530 · ClinicalTrials.gov registry record · Early Phase 1
Pressure Assessment to Improve Outcomes After TAVR: a Registry
A Early Phase 1 study of Hypertension and Quality of Life, sponsored by North Florida Foundation for Research and Education.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03923530: Completed Early Phase 1 study of Hypertension and Quality of Life, sponsored by North Florida Foundation for Research and Education.
NCT03923530 is a Early Phase 1 study of Hypertension and Quality of Life that has completed, run by North Florida Foundation for Research and Education. The registered enrollment target is 12 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03923530, a Early Phase 1 study of Hypertension and Quality of Life, has completed, sponsored by North Florida Foundation for Research and Education.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
At the Malcom Randall Veterans Affairs Medical Center (MRVAMC), invasive cardiac pressures are routinely recorded after transcatheter aortic valve replacement (TAVR) procedures. Our research has disclosed that patients with abnormal hemodynamics (narrow aortic to ventricular end-diastolic pressure difference, indexed to heart rate) suffer from high long-term mortality, compared with patients with normal hemodynamics.This hemodynamic value can be referred to as the aortoventricular index (AVi). Hypertension and diastolic dysfunction are highly co-morbid conditions among these patients. The selective aldosterone receptor antagonist eplerenone (Inspra) is approved for use in the treatment of hypertension. Research also supports that eplerenone may be able to improve diastolic function. This prospective study is interested in determining 1) the tolerability of eplerenone, and 2) feasibility of administering the Kansas City Cardiomyopathy Questionnaire (KCCQ-12) among subject with abnormal cardiac hemodynamics after TAVR. This study will set the stage for a pilot randomized trial to evaluate eplerenone versus placebo among patients with abnormal hemodynamics after TAVR.
Primary Outcome
The Kansas City Cardiomyopathy Questionnaire (KCCQ-12) is a self-administered health status survey. The KCCQ-12 has 4 domains (physical limitation, symptom frequency, quality of life, social limitation) and one summary score. Score are scaled 0-100, where 1 denotes the lowest reportable health status and 100 the highest.
Conditions Studied
Interventions
- DRUG Eplerenone
Study Locations (1)
Florida
- Malcom Randall VA Medical Center - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-06-03 |
| Est. Completion | 2020-02-27 |
| Phase | Early Phase 1 |
What the finished NCT03923530 record still lists
NCT03923530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (100% lower).
The record links to 4 conditions, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Eplerenone is the first listed.
NCT03923530 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT03923530 about?
NCT03923530 is a clinical study titled "Pressure Assessment to Improve Outcomes After TAVR: a Registry". At the Malcom Randall Veterans Affairs Medical Center (MRVAMC), invasive cardiac pressures are routinely recorded after transcatheter aortic valve replacement (TAVR) procedures. Our research has disclosed that patients with abnormal hemodynamics (narrow aortic to ventricular end-diastolic pressure d...
What is the current status of trial NCT03923530?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 12 participants. The study started on 2019-06-03. Estimated completion is 2020-02-27.
What conditions does trial NCT03923530 study?
This clinical trial studies the following conditions: Hypertension, Quality of Life, Heart Failure With Preserved Ejection Fraction, Aortic Stenosis, Calcific.
What interventions are being tested in trial NCT03923530?
The interventions under investigation include: Eplerenone (DRUG).
Who is sponsoring clinical trial NCT03923530?
This trial is sponsored by North Florida Foundation for Research and Education, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03923530 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03923530's enrollment target sits among peer trials
12 457th of 470 higher than 10 of 470 other Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Group 1)
RECRUITING · Early Phase 1
-
Cardiovascular Effects of Angiotensin-(1-7) in Obesity Hypertension
RECRUITING · Early Phase 1
-
Effect of Empagliflozin on Left Atrial Function in Adults at Risk for Heart Failure
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Imaging of Cholesterol Trafficking: Clinical Evaluation of [18F]FNP-59 in Normal Human Subjects (Groups 2, 3 & 4)
RECRUITING · Early Phase 1
-
Sympathetic Transduction in Obesity-associated Hypertension (OB-HTN)
RECRUITING · Early Phase 1
-
Reversing Glucose and Lipid-mediated Vascular Dysfunction
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI